Differences of Reasons for Alert Overrides on Contraindicated Co-prescriptions by Admitting Department
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: To reveal differences in drug-drug interaction (DDI) alerts and the reasons for alert overrides between admitting departments. Methods: A retrospective observational study was performed using longitudinal Electronic Health Record (EHR) data and information from an alert and logging system. Adult patients hospitalized in the emergency department (ED) and general ward (GW) during a 46-month period were included. For qualitative analyses, we manually reviewed all reasons for alert overrides, which were recorded as free text in the EHRs. Results: Among 14,780,519 prescriptions, 51,864 had alerts for DDIs (0.35%; 1.32% in the ED and 0.23% in the GW). The alert override rate was higher in the ED (94.0%) than in the GW (57.0%) (p < 0.001). In an analysis of the study population, including ED and GW patients, ‘clinically irrelevant alert’ (52.0%) was the most common reason for override, followed by ‘benefit assessed to be greater than the risk’ (31.1%) and ‘others’ (17.3%). The frequency of alert overrides was highest for anti-inflammatory and anti-rheumatic drugs (89%). In a sub-analysis of the population, ‘clinically irrelevant alert’ was the most common reason for alert overrides in the ED (69.3%), and ‘benefit assessed to be greater than the risk’ was the most common reason in the GW (61.4%). Conclusions: We confirmed that the DDI alerts and the reasons for alert overrides differed by admitting department. Different strategies may be efficient for each admitting department.
Abstract
Objectives: To reveal differences in drug-drug interaction (DDI) alerts and the reasons for alert overrides between admitting departments. Methods: A retrospective observational study was performed using longitudinal Electronic Health Record (EHR) data and information from an alert and logging system. Adult patients hospitalized in the emergency department (ED) and general ward (GW) during a 46-month period were included. For qualitative analyses, we manually reviewed all reasons for alert overrides, which were recorded as free text in the EHRs. Results: Among 14,780,519 prescriptions, 51,864 had alerts for DDIs (0.35%; 1.32% in the ED and 0.23% in the GW). The alert override rate was higher in the ED (94.0%) than in the GW (57.0%) (p < 0.001). In an analysis of the study population, including ED and GW patients, ‘clinically irrelevant alert’ (52.0%) was the most common reason for override, followed by ‘benefit assessed to be greater than the risk’ (31.1%) and ‘others’ (17.3%). The frequency of alert overrides was highest for anti-inflammatory and anti-rheumatic drugs (89%). In a sub-analysis of the population, ‘clinically irrelevant alert’ was the most common reason for alert overrides in the ED (69.3%), and ‘benefit assessed to be greater than the risk’ was the most common reason in the GW (61.4%). Conclusions: We confirmed that the DDI alerts and the reasons for alert overrides differed by admitting department. Different strategies may be efficient for each admitting department.
참고문헌 (33)
- Tatro DS, "Drug interaction fact" (1992), Facts and Comparisons
- Fokter N, "Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments", Wien Klin Wochenschr, 122(3-4), pp.81~88 (2010)
- Hamilton RA, "Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population", Pharmacotherapy, 18(5), pp.1112~1120 (1998)
- Jankel CA, "Epidemiology of drug-drug interactions as a cause of hospital admissions", Drug Saf, 9(1), pp.51~59 (1993)
- Pasina L, "Drug-drug interactions in a cohort of hospitalized elderly patients", Pharmacoepidemiol Drug Saf, 22(10), pp.1054~1060 (2013)
- Teich JM, "CDS Expert Review Panel. Clinical decision support in electronic prescribing: recommendations and an action plan: report of the joint clinical decision support workgroup", J Am Med Inform Assoc, 12(4), pp.365~376 (2005)
- Smithburger PL, "A critical evaluation of clinical decision support for the detection of drug-drug interactions", Expert Opin Drug Saf, 10(6), pp.871~882 (2011)
- van der Sijs H, "Drug safety alert generation and overriding in a large Dutch university medical centre", Pharmacoepidemiol Drug Saf, 18(10), pp.941~947 (2009)
- Mille F, "Analysis of overridden alerts in a drug-drug interaction detection system", Int J Qual Health Care, 20(6), pp.400~405 (2008)
- van der Sijs H, "Overriding of drug safety alerts in computerized physician order entry", J Am Med Inform Assoc, 13(2), pp.138~147 (2006)
- Weingart SN, "Physicians' decisions to override computerized drug alerts in primary care", Arch Intern Med, 163(21), pp.2625~2631 (2003)
- Rosenberg SN, "Overrides of medication alerts in ambulatory care", Arch Intern Med, 169(14), pp.1337~ (2009)
- Ahearn MD, "General practitioners' perceptions of the pharmaceutical decision-support tools in their prescribing software", Med J Aust, 179(1), pp.34~37 (2003)
- Shah NR, "Improving acceptance of computerized prescribing alerts in ambulatory care", J Am Med Inform Assoc, 13(1), pp.5~11 (2006)
- van der Sijs H, "Turning off frequently overridden drug alerts: limited opportunities for doing it safely", J Am Med Inform As soc, 15(4), pp.439~448 (2008)
- Smithburger PL, "Grading the severity of drug-drug interactions in the intensive care unit: a comparison between clinician assessment and proprietary database severity rankings", Ann Pharmacother, 44(11), pp.1718~1724 (2010)
- Bottiger Y, "SFINX-a drug-drug interaction database designed for clinical decision support systems", Eur J Clin Pharmacol, 65(6), pp.627~633 (2009)
- Tamblyn R, "A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care", J Am Med Inform Assoc, 15(4), pp.430~438 (2008)
- van der Sijs H, "Time-dependent drug-drug interaction alerts in care provider order entry: software may inhibit medication error reductions", J Am Med Inform Assoc, 16(6), pp.864~868 (2009)
- Cruciol-Souza JM, "Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital", J Pharm Pharm Sci, 9(3), pp.427~433 (2006)
- Vonbach P, "Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine", Eur J Intern Med, 19(6), pp.413~420 (2008)
- Becker ML, "Hospitalisations and emergency department visits due to drug-drug interactions:a literature review", Pharmacoepidemiol Drug Saf, 16(6), pp.641~651 (2007)
- Ahn EK, "Differences among admitting departments in alerts and alert overrides for drug-drug interaction", Pharmacoepidemiol Drug Saf, 23(4), pp.390~397 (2014)
- Grizzle AJ, "Reasons provided by prescribers when overriding drug-drug interaction alerts", Am J Manag Care, 13(10), pp.573~578 (2007)
- "Act for ingredient of contraindicated co-prescriptions of medicine" (2014)[URL]
- Isaac T, "Overrides of medication alerts in ambulatory care", Arch Intern Med, 169(3), pp.305~311 (2009)
- Taylor LK, "Reasons for physician nonadherence to electronic drug alerts", Stud Health Technol Inform, 107(Pt 2), pp.1101~1105 (2004)
- Zwart-van Rijkom JE, "Frequency and nature of drug-drug interactions in a Dutch university hospital", Br J Clin Pharmacol, 68(2), pp.187~193 (2009)
- Mantyselka P, "Pain as a reason to visit the doctor: a study in Finnish primary health care", Pain, 89(2-3), pp.175~180 (2001)
- Magnus D, "GPs' views on computerized drug interaction alerts: questionnaire survey", J Clin Pharm Ther, 27(5), pp.377~382 (2002)
- Glassman PA, "Improving recognition of drug interactions: benefits and barriers to using automated drug alerts", Med Care, 40(12), pp.1161~1171 (2002)
- Seidling HM, "What, if all alerts were specific - estimating the potential impact on drug interaction alert burden", Int J Med Inform, 83(4), pp.285~291 (2014)
- Seidling HM, "Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support", J Am Med Inform Assoc, 18(4), pp.479~484 (2011)